Use access key #2 to skip to page content.
$6.15 0.02 (0.33%)
7/18/2008 4:00 PM

Exelixis, Inc. (EXEL)

CAPS Rating:
****

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

View All Commentary (EXEL)

Recs

8

Avatar iksnamyzs (< 20) Submitted: 5/30/06 11:34 PM : Outperform Start Price: $10.36 EXEL Score: -40.19

This pick is based soley on Rulebreaker charly's pcik in the rulebreakers newsletter. He stated it's a good buy in price and expects the stock to rise based on the drugs it has in testing to be ok'd by the fed for cancer treatment.

Report this Post Replies: 0 | Reply

Featured Broker Partners